Literature DB >> 15105642

Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma.

Lisa L Lyons1, Paula E North, Fernand Mac-Moune Lai, Mark H Stoler, Andrew L Folpe, Sharon W Weiss.   

Abstract

Kaposiform hemangioendothelioma (KH) is a rare tumor of childhood often associated with Kasabach-Merritt phenomenon (KMP) and occasionally lymphangiomatosis. Although generally considered distinct from other vascular neoplasms, its rarity has precluded a thorough study of its immunophenotypic profile and long-term behavior. Thirty-three cases of KH were reviewed and immunostained for alpha-smooth muscle actin, various endothelial markers (CD31, CD34, vWf, FLI1), a platelet marker (CD61), and the juvenile hemangioma-associated markers GLUT-1 and Lewis Y antigen (LeY). In addition, the presence of HHV-8 was evaluated by RT-PCR. The patients (20 males and 13 females) ranged in age from 2 weeks to 20 years (mean 3 years 9 months). Tumors developed on the extremities (17 cases), head/neck (8 cases), and other sites (8 cases) and affected both superficial and deep soft tissue. Those in the skin presented as slightly raised blue-red lesions. More than half of the patients presented with KMP (14 of 25). Tumors consisted of irregular, infiltrating nodules of compressed vessels, which modulated between areas resembling a capillary hemangioma and Kaposi sarcoma (KS). Endothelial cells in nodules were CD31, CD34, and FLI1 positive but negative for GLUT1 and LeY. Scattered "epithelioid" or glomeruloid islands featuring endothelium associated with clusters of plump alpha-smooth muscle actin-positive pericytes, stippled hemosiderin, and CD61-positive fibrin thrombi likely represent the morphologic sites of platelet consumption. Small and large lymphatic channels occurred in 22 of 33 cases and were typically seen peripheral or deep to the main tumor mass. HHV-8 transcripts were not identified (0 of 3 cases). Follow-up information was available in 22 patients (range 8 months to 15 years; mean 2 years) and indicated that 3 died of disease, 8 were alive with disease, and 10 were alive without residual disease. Two patients developed regional perinodal soft tissue involvement, but none developed distant metastases. KH is a lesion having both a vascular and lymphatic component. Its common association with KMP probably relates in part to unique architectural features that favor turbulent blood flow and platelet activation. KH can also be reliably separated from JH by GLUT-1 and LeY immunostaining, indicating differences in the morphologic and functional attributes of the endothelium between the two lesions. The absence of HHV-8 in KH underscores a different pathogenesis from Kaposi sarcoma. Our study, the largest to date, emphasizes that mortality is due to KMP and not metastatic disease, which appears limited to regional perinodal soft tissue. Given this behavior, its continued classification as a vascular tumor of intermediate malignancy is warranted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105642     DOI: 10.1097/00000478-200405000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  68 in total

1.  Kaposiform hemangioendothelioma of the spleen in an adult: an initial case report.

Authors:  Lu Yu; Shou Jing Yang
Journal:  Pathol Oncol Res       Date:  2010-12-29       Impact factor: 3.201

2.  Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.

Authors:  Yvonne E Chiu; Beth A Drolet; Francine Blei; Manuel Carcao; Jason Fangusaro; Michael E Kelly; Alfons Krol; Sabra Lofgren; Anthony J Mancini; Denise W Metry; Michael Recht; Robert A Silverman; Wynnis L Tom; Elena Pope
Journal:  Pediatr Blood Cancer       Date:  2012-02-02       Impact factor: 3.167

3.  Epithelioid and spindle cell haemangioma of bone.

Authors:  Fiona M Maclean; Julie Schatz; Stanley W McCarthy; Richard A Scolyer; Paul Stalley; S Fiona Bonar
Journal:  Skeletal Radiol       Date:  2006-05-11       Impact factor: 2.199

4.  Kaposiform hemangioendothelioma in multiple spinal levels without skin changes.

Authors:  Jennifer W Lisle; Heather A Bradeen; Alexandra N Kalof
Journal:  Clin Orthop Relat Res       Date:  2009-04-21       Impact factor: 4.176

5.  Regression of oral Kaposi's sarcoma after combination antiretroviral therapy.

Authors:  J P S Servato; A M Loyola; P H R Spini; T H Spini; P R de Faria; Sérgio Vitorino Cardoso
Journal:  Infection       Date:  2013-07-24       Impact factor: 3.553

6.  Imaging features of kaposiform lymphangiomatosis.

Authors:  Pradeep Goyal; Ahmad I Alomari; Harry P Kozakewich; Cameron C Trenor; Antonio R Perez-Atayde; Steven J Fishman; Arin K Greene; Raja Shaikh; Gulraiz Chaudry
Journal:  Pediatr Radiol       Date:  2016-04-06

7.  Diffuse lymphangiomatous hyperplasia of the spleen with hyaline bodies. A pseudotumoral proliferation arising from the lymphatic vessels of the periarteriolar lymphatic sheath.

Authors:  Dimas Suárez-Vilela; Francisco Miguel Izquierdo; Jose Ramón Méndez; Juliana Escobar; Gerardo Urdiales; Pilar Junco
Journal:  Virchows Arch       Date:  2011-02-20       Impact factor: 4.064

8.  Adult-onset Kaposiform hemangioendothelioma of the tongue: case report and review of the literature.

Authors:  P Vashi; E Abboud; C Bier-Laning; D Gupta
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

9.  Hemangioendothelioma: a rare case of a primary intracardiac tumor.

Authors:  Andrea Beaton; Trevor Kuttler; Ali Hassan; Dilip S Nath; Christine Reyes; Richard A Jonas; Gerard R Martin
Journal:  Pediatr Cardiol       Date:  2012-03-16       Impact factor: 1.655

10.  Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases.

Authors:  M Fernanda Amary; Paul O'Donnell; Fitim Berisha; Roberto Tirabosco; Tim Briggs; Rob Pollock; Adrienne M Flanagan
Journal:  Skeletal Radiol       Date:  2013-02-05       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.